Cambridge, United Kingdom

John Trowsdale

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Mind of John Trowsdale

Introduction

John Trowsdale, a prominent inventor based in Cambridge, GB, has made significant contributions to the field of biomedical research. With three patents to his name, Trowsdale is at the forefront of innovative solutions aimed at treating serious health conditions, notably leukemia.

Latest Patents

Trowsdale's latest patents, focusing on anti-Siglec-15 antibodies, demonstrate his commitment to advancing medical treatments. These patents detail the development and potential applications of these antibodies, particularly in the treatment of leukemia, including acute myeloid leukemia. The implications of his work could pave the way for more effective therapies in oncology.

Career Highlights

Throughout his career, Trowsdale has worked with notable organizations, including Cambridge Enterprise Limited and Medimmune Limited. His roles in these companies have allowed him to leverage his expertise in research and development to create breakthrough medical innovations.

Collaborations

In his professional journey, Trowsdale has collaborated with esteemed colleagues such as Alexander Barrow and John Gawain Elvin. These partnerships have enriched his work, allowing for a blend of ideas and expertise that have been crucial in his research initiatives.

Conclusion

John Trowsdale's contributions to biomedical innovation reflect his dedication to improving patient outcomes through his research. His patents on anti-Siglec-15 antibodies stand as a testament to his impactful work, positioning him as a key figure in the fight against leukemia. As he continues his endeavors, the future holds promise for Trowsdale and his contributions to the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…